CS-8958 Clinical Pharmacology study - Safety and pharmacokinetics of nebulized laninamivir octanoate (CS-8958) after a single inhaled administration in healthy male Japanese subjects -

Trial Profile

CS-8958 Clinical Pharmacology study - Safety and pharmacokinetics of nebulized laninamivir octanoate (CS-8958) after a single inhaled administration in healthy male Japanese subjects -

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 27 Jun 2017 Results evaluating the the safety and pharmacokinetics of nebulized laninamivir octanoate and laninamivir in healthy male Japanese subjects, presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.
    • 17 Jun 2016 Status changed from not yet recruiting to completed.
    • 17 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top